Banc of California, Inc.（BANC）资讯与事件BANCBanc of California, Inc.

Goldman Sachs, JPMorgan, and Others to Report Earnings on October 13

Goldman Sachs, JPMorgan, Wells Fargoand Citiare scheduled to report earnings on October 13, while Morgan Stanleyand Bank of Americaare expected to announce earnings the day after. What to watch for:OUTLOOK:JPMorgan is expected to post third quarter EPS of $5.93 on revenue of $51.2B, Goldman Sachs $12.87 on $16.8B, Wells Fargo $1.85 on $22.3B, Citi $2.65 on $23.7B, Bank of America $1.10 on $30.6B, and Morgan Stanley $2.93 on $19.9B.STOCK ACTION:JPMorgan and Citi shares are down about 4% over the past month, Goldman Sachs nearly 10%, Wells Fargo more than 6%, and Bank of America and Morgan Stanley over 8%.AI SCARE TRADE:Ahead of quarterly results, Wells Fargo analyst Mike Mayo says the firm remains constructive on bank stocks over the next year but urges investors to "mind the gap" given rate concerns and, to a lesser extent, narratives around AI and the mid terms. Wells argues three emerging negative themes are "overdone": the AI "scare trade," which it expects to reverse as earnings reinforce trust driven deposit moats; mid term election noise that may slow deregulation but not derail it; and worries that higher rates are hurting capital markets, loan growth and credit, though the firm notes potential extra provisions tied to data center credit issues and softer FICC.Wells continues to see "Goliath as winning" in deposit competition. Its top pick remains Citi, though it expects a so so Q3, followed by Bank of America with relatively weak capital markets trends. Among large regionals, the firm favors Fifth Thirdand PNC Financial. In mid caps, Wells prefers Banc of California, Old National Bancorpand Pinnacle Financial, while remaining cautious near term on BOK Financial, BankUnitedand Commerce Bancshares.SELECTION 'IS CRITICAL':TD Cowen resumed coverage of 16 large-cap banks, assigning Hold ratings to JPMorgan, Bank of America and Morgan Stanley, and Buy ratings to Wells Fargo, Citi and Goldman Sachs. The firm says the fundamental backdrop "seems about as good as it gets," but views stock selection as "critical" given its stronger conviction in sector fundamentals than in current valuations.

Banc of California CEO: Capital Levels Near 10% by Year-End

Asked while presenting at the Barclays Annual Global Financial Services Conference about balancing capital build with opportunities to grow the balance sheet, Banc of California CEO Jared Wolff said: "We have plenty of capital. We ended the second quarter in the low nines. We were picking up capital pretty quickly, and so we will be returning close to 10 by the end of the year. If the risk-weighted adjustments take hold, if the Fed rules take hold, we will expect to pick up 50 to 60 basis points of additional CET1 when those rules take effect. We are building up capital pretty quickly. I think we should be at 10 or have 10 clearly in sight to start buying back stock. We have a repurchase authorization that is out there. If we're in the fourth quarter, everything is moving along, our capital levels are on target, and we have confirmation that the new risk ratings will take effect, I don't think we would hesitate to buy back stock if the conditions were right. If we haven't heard about those regulatory capital rules and we don't know with certainty, then I think we'll wait till we get above 10 to start buying back stock."

Allotera Therapeutics Closes $35M Financing Round

Allotera Therapeutics announced the closing of a $35M financing round comprising equity and venture debt. The company also introduced its new name, Allotera Therapeutics, reflecting its sharpened focus on advancing off-the-shelf CAR-T cell therapies for patients with T-cell cancers . The financing brings Allotera's total capital raised to $150M, building on the company's $115M Series C announced in late 2025. Proceeds will primarily support the ongoing global pivotal T-RRex clinical trial of Soficabtagene Geleucel, also known as Sofi-cel, in relapsed or refractory T-ALL/T-LBL, as well as advance platform capabilities, operational scale-up, and continued team growth. The Series C was led by Fidelity Management & Research Company, with participation from all existing investors. The current extension includes additional participation from Lightchain Capital and BioGenerator, as well as new investors, including Blood Cancer United's Therapy Acceleration Program and others. The venture debt was provided by Banc of California.